Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: role of granulocyte macrophage colony-stimulating factor

被引:28
作者
Henze, C [1 ]
Hartmann, A [1 ]
Lescot, T [1 ]
Hirsch, EC [1 ]
Michel, PP [1 ]
机构
[1] Hop La Pitie Salpetriere, INSERM, U679, F-75013 Paris, France
关键词
astrocytes; inflammation; microglia; MPP+; Parkinson's disease; proliferation;
D O I
10.1111/j.1471-4159.2005.03416.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is evidence that an inflammatory microglial reaction participates in the pathophysiology of dopaminergic neuronal death in Parkinson's disease and in animal models of the disease. However, this phenomenon remains incompletely characterized. Using an in vitro model of neuronal/glial mesencephalic cultures, we show that the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+) stimulates the proliferation of microglial cells at concentrations that selectively reduce the survival of DA neurones. The mitogenic action of MPP+ was not the mere consequence of neuronal cell demise as the toxin produced the same effect in a model system of neuronal/glial cortical cultures, where target DA neurones are absent. Consistent with this observation, the proliferative effect of MPP+ was also detectable in neurone-free microglial/astroglial cultures. It disappeared, however, when MPP+ was added to pure microglial cell cultures suggesting that astrocytes played a key role in the mitogenic mechanism. Accordingly, the proliferation of microglial cells in response to MPP+ treatment was mimicked by granulocyte macrophage colony-stimulating factor (GM-CSF), a proinflammatory cytokine produced by astrocytes and was blocked by a neutralizing antibody to GM-CSF. Thus, we conclude that the microglial reaction observed following MPP+ exposure depends on astrocytic factors, e.g. GM-CSF, a finding that may have therapeutic implications.
引用
收藏
页码:1069 / 1077
页数:9
相关论文
共 35 条
[1]   PARKINSONS-DISEASE - PATHOPHYSIOLOGY [J].
AGID, Y .
LANCET, 1991, 337 (8753) :1321-1324
[2]   Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure [J].
Barcia, C ;
Bahillo, AS ;
Fernández-Villalba, E ;
Bautista, V ;
Poza, MPY ;
Fernández-Barreiro, A ;
Hirsch, EC ;
Herrero, MT .
GLIA, 2004, 46 (04) :402-409
[3]   GM-CSF affects hypothalamic neurotransmitter levels in mice: Involvement of interleukin-1 [J].
Bianchi, M ;
Clavenna, A ;
Bondiolotti, GP ;
Ferrario, P ;
Panerai, AE .
NEUROREPORT, 1997, 8 (16) :3587-3590
[4]   Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease [J].
Breidert, T ;
Callebert, J ;
Heneka, MT ;
Landreth, G ;
Launay, JM ;
Hirsch, EC .
JOURNAL OF NEUROCHEMISTRY, 2002, 82 (03) :615-624
[5]   Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo [J].
Dehmer, T ;
Lindenau, J ;
Haid, S ;
Dichgans, J ;
Schulz, JB .
JOURNAL OF NEUROCHEMISTRY, 2000, 74 (05) :2213-2216
[6]  
DIMONTE DA, 1992, J PHARMACOL EXP THER, V261, P44
[7]   Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease [J].
Du, YS ;
Ma, ZZ ;
Lin, SZ ;
Dodel, RC ;
Gao, F ;
Bales, KR ;
Triarhou, LC ;
Chernet, E ;
Perry, KW ;
Nelson, DLG ;
Luecke, S ;
Phebus, LA ;
Bymaster, FP ;
Paul, SM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (25) :14669-14674
[8]   Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum [J].
He, Y ;
Appel, S ;
Le, WD .
BRAIN RESEARCH, 2001, 909 (1-2) :187-193
[9]  
HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0
[10]  
Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214